2012-02-14-世界卫生组织-Second_Global_GLC_committee_meeting_31页_401kb

The 2nd Meeting of the Global GLC Committee, held February 28-29, 2012, at WHO Geneva, focused on advancing MDR-TB management, services, and scaling up efforts. Key updates included progress from the prior meeting, with improved regional GLC implementation and increased SLD procurement. Discussions addressed the availability and accessibility of second-line anti-TB drugs, advocating for MDR-TB through enhanced strategies and partnerships. Responses were provided for emerging issues like the "Totally Drug Resistant Tuberculosis" event, emphasizing the need for evaluation and data-driven recommendations.

Major recommendations involved optimizing GDF operations, strengthening SLD affordability, refining advocacy, and assessing the global framework. Absence of evidence for treatments like clofazimine and high drug costs were flagged. The meeting underscored the importance of collaboration, workforce capacity, and accountability to universal MDR-TB access by 2015. Post-meeting, recommendations were solidified on agenda items, including teleconferences for technical support and burdened timelines for regional GLCs.